Bladder cancer in women

International Urogynecology Journal

Volumn 10, Issue 3, 1999, Pages 207-212

  Van Der Poel, H G ^a   Mungan, N A ^a   Witjes, J A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bladder cancer; Incidence; Prognosis; Risk factors; Women

Indexed keywords

TUMOR MARKER;

BLADDER CANCER; BLADDER SURGERY; CANCER STAGING; COFFEE; COMPARATIVE STUDY; CYSTECTOMY; DIAGNOSTIC ACCURACY; DISEASE COURSE; ENVIRONMENTAL FACTOR; FEMALE; FOOD; GENDER; HUMAN; IATROGENIC DISEASE; MALE; OCCUPATIONAL EXPOSURE; ORTHOTOPIC BLADDER REPLACEMENT; PRIORITY JOURNAL; RADIOTHERAPY; REVIEW; SMOKING; STATISTICAL ANALYSIS; TRANSITIONAL CELL CARCINOMA; UNITED STATES; URINARY TRACT INFECTION; UTERINE CERVIX CANCER; VIRUS INFECTION; WART VIRUS;

EID: 0033057412     PISSN: 09373462     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001920050046     Document Type: Review

References (65)

1. Mommsen S, Aagaard J. Sell A. Presenting symptoms, treatment delay and survival in bladder cancer. Scand J Urol Nephrol 1983;17:163-166
2. Kiemeney LA, Witjes JA, Heijbroek RP, Verbeek AL, Debruyne FMJ. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993;150:60-64
3. Hermansen DK, Badalament RA, Fair WR, Kimmel M, Whitmore WF, Melamed MR. Detection of bladder carcinoma in females by flow cytometry and cytology. Cytometry 1989;10:739-742
4. van der Poel HG, Witjes JA, Schalken JA, Debruyne FMJ. Automated image analysis for bladder cancer. Invited editorial. Urol Res 1998;26:1-5
5. van der Poel HG, Witjes JA, van Stratum P, Boon ME, Debruyne FM, Schalken JA. Quanticyt: karyometric analysis of bladder washing for patients with superficial bladder cancer. Urology 1996;48:357-364
6. Witjes JA, van der Poel HG, van Balken MR, Debruyne FMJ, Schalken JA. Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer. Eur Urol 1998;33:387-391
7. van der Poel HG, van Balken MR, Schamhart DH et al. Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer. Urology 1998;51:44-50
8. Soloway MS, Briggman V, Carpinito GA et al. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996;156:363-367
9. Sarosdy MF, deVere-White RW, Soloway MS et al. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 1995;154:379-383
10. The United Kingdom and Eire Bladder Tumour Antigen Study Group. The use of the bladder-tumour associated analyte test to determine the type of cystoscopy in the follow-up of patients with bladder cancer. Br J Urol 1997;79:362-366
11. Silverman DT, Hartge P, Morrison AS, Devesa SS. Epidemiology of bladder cancer. Hematol Oncol Clin N Am 1992;6:1-30
12. Hartge P, Harvey EB, Marston W. Unexplained excess risk of bladder cancer in men. J Natl Cancer Inst 1990;82:1636-1641
13. Kunze E, Chang-Claude J, Frentzel-Beyme R. Life style and occupational risk factors in bladder cancer in Germany. A case-control study. Cancer 1992;69:1776-1790
14. Donate F, Boffetta P, Fazioli R, Aulenti V, Gelatti U, Porru S. Bladder cancer, tobacco smoking, coffee and alcohol drinking in Brescia, northern Italy. Eur J Epidemiol 1997;13:795-800
15. Brummer B, White E, Vaughan TL, Cheney CL. Fluid intake and the incidence of bladder cancer among middle-aged men and women in a three-county area of western Washington. Nutr Cancer 1997;29:163-168
16. England A, Andersen A, Haldorsen T, Tretli S. Smoking habits and risk of cancers other than lung cancer: 28 years' follow-up of 26,000 Norwegian men and women. Cancer Causes Control 1996;7:497-506
17. Bedwani R, el-Khwksy F, Renganathan E et al. Epidemiology of bladder cancer in Alexandria, Egypt: tobacco smoking. Int J Cancer 1997;73:64-67
18. Thorn M, Bergström R, Johansson AM, Ramström L, Persson I, Malmström PU. Trends in urinary bladder cancer incidence in Sweden 1960-93 with special reference to histophathology, time period, birth control, and smoking. Cancer Causes Control 1997;8:560-576
19. Folsom AR, Zhang S, Sellers TA, Zheng W, Kushi LH, Cerhan JR. Cancer incidence among women living on farms: findings from the Iowa Women's Heatlh Study. J Occup Environ Med 1996;38:1171-1176
20. Ruder AM, Ward EM, Brown DP. Cancer mortality in female and male dry-cleaning workers. J Occup Med 1994;36:867-864
21. Silverman DT, Levin LI, Hoover RN. Occupatioinal risks of bladder cancer among white women in the United States. Am J Epidemiol 1990;132:453-461
22. Salminen E, Pukkala E, Teppo L, Pyrhonen S. Subsequent primary cancers following bladder cancer. Eur J Cancer 1994;30:303-307
23. Hartveit F, Maehle BO. One of 8 women with bladder neoplasia may have concomitant gastrointestinal pathology including cancer. J Urol 1989;142:716-718
24. Cantor RP, Lynch CF, Johnson D. Bladder cancer, parity, and age at first birth. Cancer Causes Control 1992;3:57-62
25. Krouse TB. Menopausal pathology. In: Eskin BA, ed. The menopause: comprehensive management. New York: Masson Publishing USA, 1980:9
26. Radis CD, Kahl LE, Baker GL et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 1995;38:1120-1127
27. de Ridder D, van Poppel H, Demonty L. et al. Bladder cancer in patients with multiple sclerosis treated with cyclophosphamide. J Urol 1998;159:1881-1884
28. Kleinerman RA, Boice JD, Storm HH et al. Second primary cancer after treatment for cervical cancer. An international cancer registries study. Cancer 1995;76:442-452
29. Quilty PM, Kerr GR. Bladder cancer following low or high dose pelvic irridation. Clin Radiol 1987;38:583-585
30. Mansson A, Anderson H, Colleen S. Time lag to diagnosis of bladder cancer - influence of psychosocial parameters and level of health-care provision. Scand J Urol Nephrol 1993;27:363-369
31. Kjaer SK, Knudsen JB, Sørensen BL, Möller Jensen O. The Copenhagen case-control study of bladder cancer. V. Review of the role of urinary-tract infection. Acta Oncol 1989;28:631-636
32. Gonzalez CA, Errezola M, Izarzugaza I et al. Urinary infection, renal lithiasis, and bladder cancer in Spain. Eur J Cancer 1991;27:498-500
33. Dolin PJ, Darby SC, Beral V. Paraplegia and squamous cell carcinoma of the bladder in young women: findings from a case-control study. Br J Cancer 1994;70:167-168
34. La Vecchia C, Negri E, D'Avanzo B, Savoldelli R, Franceschi S. Genital and urinary tract diseases and bladder cancer. Cancer Res 1991;51:629-631
35. Kantor AF, Harge P, Hoover RN, Fraumeni JF. Epidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladder. Cancer Res 1988;48:3853-3855
36. Mvula M, Iwasaka T, Iguchi A, Nakamura S, Masaki Z, Sugimori H. Do human papillomaviruses have a role in the pathogenesis of bladder carcinoma? J Urol 1996;155:471-474
37. Lopez-Beltran A, Munoz A. Transitional cell carcinoma of the bladder: low incidence of human papillomavirus DNA detected by the polymerase chain reaction and in situ hybridization. Histopathology 1995;26:565-569
38. Tenti P, Zappatore R, Romagnoli S et al. p53 overexpression and human papillomavirus infection in transitional cell carcinoma of the urinary bladder: correlation with histological parameters. J Pathol 1996;178:65-70
39. Aynaud O, Tranbaloc P, Orth G. Lack of evidence for a role of human papillomaviruses in transitional cell carcinoma of the bladder. J Urol 1998;159:86-89
40. Boucher NR, Anderson JB. Human papillomavirus and bladder cancer. Int Urogynecol J 1997;8:354-357
41. Brenner H, Siegle S, Stegmaier C, Ziegler H. Second primary malignancies following gynecological tumours in Saarland, Germany, 1968-1987. J Cancer Res Clin Oncol 1993;119:179-183
42. Fisher G, Harlow SD, Schottenfeld D. Cumulative risk of secondary primary cancers in women with index primary cancers of uterine cervix and incidence of lower anogenital tract cancers, Michigan, 1985-1992. Gynecol Oncol 1997;64:213-223
43. Koraitim MM, Metwalli NE, Atta MA, el-Sadr AA. Changing age incidence and pathological types of schistosoma-associated bladder carcinoma. J Urol 1995;154:1714-1716
44. Badawi AF, Mostafa MH, Probert A, O'Connor PJ. Role of schistosomiasis in human bladder cancer: evidence of association, aetiological factors, and basic mechanisms of carcinogenesis. Eur J Cancer 1995;4:45-69
45. Helling-Giese G, Kjetland EF, Gundersen SG et al. Schistosomiasis in women: manifestations in the upper reproductive tract. Acta Trop 1996;62:225-238
46. Johansson SL, Cohen SM. Epidemiology and aetiology of bladder cancer. Semin Surg Oncol 1997;13:291-300
47. Kiemeney LALM, Coebergh JWW, Koper NP et al. Bladder cancer incidence and survival in the south-eastern part of the Netherland, 1975-1989. Eur J Cancer 1994;30:1134-1139
48. Fleshner NE, Herr HW, Stewart AK, Murphy GP, Mettlin C, Menck HR. The national cancer data base report on bladder carcinoma. Cancer 1996;78:1505-1510
49. Malmström PU, Thorn M, Lindblad P, Bergström R, Adami HO. Increasing survival of patients with urinary bladder cancer. A nationwide study in Sweden 1960-1986. Eur J Cancer 1993;29:1868-1872
50. Levi F, La Vecchia C, Randimbison L, Franceschi S. Incidence of infiltrating cancer following superficial bladder carcinoma. Int J Cancer 1993;55:419-421
51. Witjes JA, Kiemeney LALM, Verbeek ALM, Heijbroek RP, Debruyne FMJ. Random bladder biopsies and the risk of recurrent superficial bladder cancer. A prospective study in 1026 patients. World J Urol 1992;10:231-234
52. Lane DP. Cancer: p53, guardian of the genome. Nature 1992;358:15-16
53. Esrig D, Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259-1264
54. Storey A, Thomas M, Kalita A et al. Role of a p53 polymorphism in the development of human papilloma virus associated cancer. Nature 1998;393:229-234
55. Suzuki H, Komiya A, Aida S, Ito H, Yatani R. Shimazaki J. Detection of human papillomavirus DNA and p53 gene mutations in human prostate cancer. Prostate 1996;28:318-24
56. Krege S, Giani G, Meyer R, Otto T, Rubben H. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guérin. J Urol 1996;156:962-966
57. Kurth KH, Denis L, Bouffioux Ch et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 1995;31:1840-1846
58. Stenzl A, Colleselli K, Poisel S, Feichtinger H, Bartsch G. The use of neobladders in women undergoing cystectomy for transitional-cell cancer. World J Urol 1996;14:15-21
59. Stein JP, Cote RJ, Freeman JA et al. Indications for lower urinary tract reconstructioin in women after cystectomy for bladder cancer: a pathological review of female cystectomy specimens. J Urol 1995;154:1329-1333
60. Hautmann RE, Egghart G, Frohneberg D, Miller K. The ileal neobladder. J Urol 1988;139:39-42
61. Studer UE, Danuser H, Merz WW, Springer JP, Zingg EJ. Experience in 100 patients with an ilieal low pressure bladder substitute combined with an afferent tubular isoperistaltic segment. J Urol 1995;154:49-56
62. Coloby PJ, Kakizoe T, Tobisu K, Sakamoto M. Urethral involvement in female bladder cancer patients: mapping of 47 consecutive cystourethrectomy specimens. J Urol 1994;152:1438-1442
63. Stenzl A, Draxl H, Posch B, Colleselli K, Falk M, Bartsch G. The risk of urethral tumors in female bladder cancer: can the urethra be used for orthotopic reconstruction of the lower urinary tract? J Urol 1995;153:950-955
64. Chen ME, Pisters LL, Malpica A, Pettaway CA, Dinney CP. Risk of urethral, vaginal and cervical involvement in patients undergoing radical cystectomy for bladder cancer: results of contemporary cystectomy series from M.D. Anderson Cancer Center. J Urol 1997;157:2120-2123
65. De Paepe ME, Andre R, Mahadevia P. Urethral involvement in female patients with bladder cancer. A study of 22 cystecotmy specimens. Cancer 1990;65:1237-1241